

Manufacturing and Marketing permission issued from SND Division from 01.01.2017 to 17.07.2017.

S.No.	Drug Name	Indication	Date of Approval
1	Sofosbuvir 400 mg film coated Tablet	In combination with other medicinal products for the treatment of Chronic Hepatitis C (CHC) in adults	16.02.2017
2	Hydralazine tablets BP 25 mg (Additional Strength)	For moderate to severe hypertension (in conjunction with a β -adrenoceptor blocking agent or diuretic) and hypertensive crisis.	23.02.2017
3	Hydralazine tablets BP 50 mg (Additional Strength)	For moderate to severe hypertension (in conjunction with a β -adrenoceptor blocking agent or diuretic) and hypertensive crisis.	23.02.2017
4	Bendamustine hydrochloride injection 90 mg/mL (Fill volume 0.5 mL in 2 ml capacity vial & 2 mL filled in 2 mL capacity vial)	<ol style="list-style-type: none"> 1. For the treatment of patients with chronic lymphocytic leukemia 2. For the use in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) that has Progressed During or Within six months of treatment with Rituximab or a Rituximab containing Regimen. 	02.03.2017
5	Eltrombopagolamine 25 mg/50 mg tablets (Additional indication)	For the treatment of thrombocytopenia in paediatric patients 1 year and older with chronic immune(idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. (It should be used only in patients with ITP whose degree of Thrombocytopenia and clinical condition increase the risk for bleeding. It should not be used in an attempt to normalize platelet counts).	02.03.2017
6	Azacitidine for injection 100 mg	For the treatment of adult patients with all subtypes of Myelodysplastic Syndrome With the condition: to be sold by retail on the prescription of Oncologist only	07.03.2017
7	Methylcobalamin 1500 mcg orally disintegrating strips	For the treatment of Diabetic Neuropathy and peripheral Neuropathy	10.03.2017
8	Cefditoren Pivoxil dry powder for suspension 100 mg/5 mL	For the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the condition listed below <ul style="list-style-type: none"> • Acute Bacterial Exacerbation of Chronic Bronchitis • Community-Acquired pneumonia • Pharyngitis/Tonsillitis 	30.03.2017

		<ul style="list-style-type: none"> • Acute sinusitis • Uncomplicated skin and skin-structure infections. 	
9	Thiotepa Powder for concentrate for solution for infusion 100 mg(Additional strength & indication)	<ol style="list-style-type: none"> 1. With or without total body irradiation(TBI), as conditioning treatment prior to allogenic or autologous hematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and pediatrics patients; 2. When high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumors in adult and pediatrics patients. <p>With the condition: to be sold by retail on the prescription of Hematologist only</p>	06.04.2017
10	Thiotepa Powder for concentrate for solution for infusion 15mg (Additional indication)	<ol style="list-style-type: none"> 1. With or without total body irradiation(TBI), as conditioning treatment prior to allogenic or autologous hematopoietic progenitor cell transplantation(HPCT) in haematological disease in adult and pediatrics patients; 2. When high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumors in adult and pediatrics patients. <p>With the condition: to be sold by retail on the prescription of Hematologist only</p>	06.04.2017
11	Bortezomib for Injection (i.v) 1 mg/vial (Additional indication)	For the treatment of patients with mantle cell lymphoma With the condition: to be sold by retail on the prescription of Oncologist only	11.04.2017
12	Bortezomib 3.5 mg/vial Powder for solution for injection (i.v/s.c) (Additional indication)	For the treatment of patients with mantle cell lymphoma With the condition: to be sold by retail on the prescription of Oncologist only	11.04.2017
13	Mesalamine Delayed Release Tablets 800 mg (Additional dosage form)	For the treatment of mild to moderate acute exacerbations of ulcerative colitis and for the maintenance of remission of ulcerative colitis. With the condition: to be sold by retail on the prescription of Specialist/Gastroenterologist only	11.04.2017
14	Teneligliptin Film coated Tablet 20 mg	For the treatment of Type 2 Diabetes Mellitus as a monotherapy adjunct to diet and exercise.	28.04.2017
15	Ticagrelor 60 mg tablets (Additional strength & indication)	Indicated for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing a thrombotic event. With the condition: to be sold by retail on the	02.05.2017

		prescription of Cardiologist/Internal Medicine Speciality only	
16	Daclatasvir Tablet 30 mg	“For use with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection”. With the condition: to be sold by retail on the prescription of Hepatologist only	24.05.2017
17	Daclatasvir Tablet 60 mg	“For use with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection”. With the condition: to be sold by retail on the prescription of Hepatologist only	24.05.2017
18	Rosuvastatin Tablets 15 mg	<ul style="list-style-type: none"> a. Treatment of patients with primary hypercholesterolemia or mixed dyslipidemia, homozygous familial hypercholesterolemia as an adjunct to diet,when response to diet and exercise is inadequate b. As an adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. c. As an adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower total C and LDL-C to target levels. d. Risk reduction of Myocardial Infarction stroke and arterial revascularization procedure in patients without clinically evident CHD but with multiple risk factors. e. As an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (type-III hyperlipoproteinemia). f. As adjunct to diet to reduce total-C,LDL-C and ApoB levels in adolescent boys and girls,who are atleast one year post-menarche,10-17 years of age with heterozygous familial hypercholesterolemia if after and adequate trial of diet therapy the following findings are present:LDL-C >190 mg/dL or > 160 mg/dL and there is a positive family history of premature cardiovascular disease (CVD) or two or more CVD risk factors. 	30.05.2017
19	Rosuvastatin film coated Tablets 30 mg	<ul style="list-style-type: none"> a. Treatment of patients with primary hypercholesterolemia or mixed dyslipidemia, homozygous familial hypercholesterolemia as an adjunct to diet,when response to diet and exercise is inadequate b. As an adjunctive therapy to diet for the 	30.05.2017

		<p>treatment of adult patients with hypertriglycerdemia.</p> <p>c. As an adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower total C and LDL-C to target levels.</p> <p>d. Risk reduction of Myocardial Infarction stroke and arterial revascularization procedure in patients without clinically evident CHD but with multiple risk factors.</p> <p>e. As an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (type-III hyperlipoproteinemia).</p> <p>f. As adjunct to diet to reduce total-C, LDL-C and ApoB levels in adolescent boys and girls, who are atleast one year post-menarche,10-17 years of age with heterozygous familial hypercholesterolemia if after and adequate trial of diet therapy the following findings are present: LDL-C >190 mg/dL or > 160 mg/dL and there is a positive family history of premature cardiovascular disease (CVD) or two or more CVD risk factors.</p>	
20	Abiraterone Acetate Tablet 500 mg	<p>1. In combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer who have received prior chemotherapy containing docetaxel</p> <p>2. For the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated with prednisone or prednisolone.</p> <p>With the condition: to be sold by retail on the prescription of Oncologist only</p>	12.07.2017
21	Enzalutamide hard Gelatin Capsules 40 mg	<p>For the treatment of adults with metastatic castration resistant prostate cancer whose disease has progressed on or after Docetaxel therapy.</p> <p>With the condition: to be sold by retail on the prescription of Oncologist only</p>	12.07.2017